Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

NCT05132088 | Completed Phase 3 FDA Drug

• 2 other identifiers: NN9932-4738U1111-1258-7561
• Study Type: interventional
• Target: 201
• Locations: 2 countries
• Sites: 13

Brief Summary

Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation. Semaglutide tablets are new medicine being tested to treat overweight and obesity. Doctors in many countries can already prescribe semaglutide tablets at lower doses to treat type 2 diabetes. Participants will get semaglutide or placebo tablets for 68 weeks and will need to take 1 tablet every morning. In addition to taking the medicine, participants will have talks with study staff about:

• healthy food choices
• how to be more physically active
• what participants can do to lose weight The study will last for about 1½ year. Participants will have 14 clinic visits and 7 phone calls with the study healthcare professional. Blood samples will be taken at 12 visits. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period. If participants are a woman and are able to become pregnant, participants will be checked for pregnancy via urine tests.

Conditions

Overweight and Obesity

Outcome Measures

Primary Outcomes (2)

• Relative change in body weight

  Percentage-point

  From baseline (week 0) to end of treatment (week 68)

• Achievement of body weight reduction greater than or equal to 5% (Yes/No)

  Count of participants

  At end of treatment (week 68)

Secondary Outcomes (20)

• Achievement of body weight reduction greater than or equal to 10% (Yes/No)

  At end of treatment (week 68)

• Change in Physical function domain (5-items) score (IWQOL-Lite-CT)

  From baseline (week 0) to end of treatment (week 68)

• Achievement of body weight reduction greater than or equal to 15% (Yes/No)

  At end of treatment (week 68)

• Achievement of body weight reduction greater than or equal to 20% (Yes/No)

  At end of treatment (week 68)

• Change in body mass index (BMI)

  From baseline (week 0) to end of treatment (week 68)

Study Arms (2)

oral semaglutide 50 mg once daily

EXPERIMENTAL

All participants will get semaglutide or placebo tablets, 1 tablet every morning.

Drug: semaglutide 50 mg

oral semaglutide placebo once daily

PLACEBO COMPARATOR

All participants will get semaglutide or placebo tablets, 1 tablet every morning.

Drug: placebo (semaglutide)

Interventions

semaglutide 50 mg DRUG

Participants will have semaglutide for 68 weeks and will have 1 tablet every morning. Dose gradually increased to 50 mg.

oral semaglutide 50 mg once daily

placebo (semaglutide) DRUG

Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.

oral semaglutide placebo once daily

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are eligible to be included in the study only if all the following criteria apply:
• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• Male or female, age above or equal to 18 years at the time of signing informed consent
• Body mass index (BMI) of greater than or equal to 27.0 kg/m\^2 with greater than or equal to 2 weight related comorbidities (treated or untreated) according to the JASSO guideline or BMI greater than or equal to 35.0 kg/m\^2 with greater than or equal to1 weight related comorbidity (treated or untreated) according to the JASSO guideline. At least one comorbidity should be hypertension, dyslipidaemia or type 2 diabetes (T2D)
• History of at least one self-reported unsuccessful dietary effort to lose body weight
• Diagnosed with T2D greater than or equal to 180 days prior to screening
• Treated with either diet and exercise alone or stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic drugs (OADs) alone or in any combination (metformin, α-glucosidase (AGI), sulphonylureas (SU), glinides, SGLT2i (sodium-glucose co-transporter 2 inhibitor) or thiazolidinediones)
• HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) as measured by central laboratory at screening

You may not qualify if:

• Participants without T2D only:
• HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening
• History of type 1 or type 2 diabetes
• Treatment with glucose-lowering agent(s) within 90 days prior to screening
• Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR brlow 15 ml/min/1.73 m\^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO) 2012 classification by the central laboratory at screening
• Participants with T2D at screening only:
• Receipt of any other anti-diabetic investigational drug within 90 days prior to screening for this study, or receipt of any investigational drugs not affecting diabetes within 30 days prior to screening for this study
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
• Renal impairment measured as eGFR value of below 30 mL/min/1.73 m\^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening
• In participants treated with SGLT2i, renal impairment measured as eGFR value of below 60 mL/min/1.73 m\^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening
• The following criteria apply to all participants:
• Obesity-related:
• Treatment with any medication indicated for weight management within 90 days prior to screening
• Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed greater than 1 year prior to screening, (2) lap banding, if the band has been removed greater than 1 year prior to screening, (3) intragastric balloon, if the balloon has been removed greater than 1 year prior to screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed greater than 1 year prior to screening
• Uncontrolled thyroid disease per investigators discretion

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (13)

Iryouhoujinsyadan Shoureikan Shinsapporo Seiryou Hospital

Sapporo, Hokkaido, 004-0004, Japan

Location

Tsuruma Kaneshiro Diabetes Clinic

Yamato-shi, Kanagawa, 242-0004, Japan

Location

OCROM Clinic

Suita-shi, Osaka, 565-0853, Japan

Location

Naka Kinen Clinic

Ibaraki, 311-0113, Japan

Location

Toranomon Hospital, Endocrinology and Metabolism

Minato-ku, Tokyo, 105-8470, Japan

Location

Osaka University Hospital

Osaka, 565-0871, Japan

Location

Takatsuki Red Cross Hospital

Osaka, 569-1045, Japan

Location

Tokyo Center Clinic

Tokyo, 103-0028, Japan

Location

ToCROM Clinic

Tokyo, 160-0008, Japan

Location

Kyungpook National University Hospital

Daegu, 41944, South Korea

Location

Seoul National University Bundang Hospital

Gyeonggi-do, 13620, South Korea

Location

Gachon University Gil Medical Center

Incheon, 21565, South Korea

Location

Kangbuk Samsung Hospital

Seoul, 03181, South Korea

Location

Related Publications (1)

• Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, Kim KK; OASIS 2 Investigators. Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. JAMA Intern Med. 2025 Oct 1;185(10):1206-1217. doi: 10.1001/jamainternmed.2025.3599.

  PMID: 40758358 DERIVED

MeSH Terms

Conditions

Overweight; Obesity

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency (dept. 1452)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 11, 2021
• First Posted: November 24, 2021
• Study Start: November 16, 2021
• Primary Completion: July 11, 2023
• Study Completion: September 1, 2023
• Last Updated: June 6, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share

Locations

JP (9); KR (4)